Skip To The Main Content
Parenteral Drug Association Connecting People, Science and Regulation ®

Practical Application of Phase-Appropriate GMP & Quality to Clinical Development of ATMPs

Jun 07 - Jun 07, 2018 |
Jun 07, 2018 |
Novotel Amsterdam Schiphol Airport Hotel | Amsterdam, The Netherlands
  • Education
  • Europe
Add event to: ICal Outlook Google Calendar

There has been a surge in clinical development of Advanced Therapy Medicinal Products (ATMPs), also known as Cellular and Gene Therapy (CGT) Products in the USA. Many startup companies, hospitals, universities, and now even large biopharmaceutical companies, are planning or have already entered into manufacturing these genetically engineered virus and human cell products for clinical studies. While the ground rules for good manufacturing practices (GMPs) and Quality of recombinant protein and monoclonal antibody manufacturing and control are well established, for the ATMPs these are still under development.

ATMP manufacturing and control presents unique GMP and Quality challenges, such as the heightened concern about the safety and consistency of the starting material, the safety and quality of the raw materials added during processing, the need to protect against adventitious agent contamination during the entire manufacturing cycle, the limitations of the analytical methods available to characterize these virus and cell products, and the reality that the administered clinical medicinal product is a complex living organism.

Patients in these clinical development programs need to be protected by common sense GMPs and Quality. The available regulatory authority guidance documents (both EMA and FDA) for ATMPs will be thoroughly examined. In addition, the core principles presented in PDA’s 2016 Technical Report 56 ‘Application of Phase-Appropriate Quality System and cGMP to the Development of Therapeutic Protein Bulk Drug Substance (API)’ will be adapted to ATMPs.

Who Should Attend

This course is designed for those involved or interested in the manufacturing, quality and GMP compliance of ATMPs during clinical stages of development, including Senior Managers, Directors and Managers/Supervisors, QA/QC, Regulatory, Manufacturing and Process Development personnel.

Learning Objectives

Upon completion of this course, you will be able to:

  • Explain the importance and underlying GMP and Quality principles for manufacturing, control and compliance of ATMPs during clinical stages of development
  • Appreciate the GMP and Quality similarities and differences between protein medicinal products and ATMPs
  • Appropriately apply phase-appropriate GMPs and Quality Principles to the clinical development of ATMPs

Instructors

John Geigert, PhD, RAC, President, BioPharmaceutical Quality Solutions
John Geigert has been a consultant for the past 15 years, specializing in CMC regulatory strategy for the biopharmaceutical industry. He has held senior leadership positions in industry as Vice President of Quality for both IDEC Pharmaceuticals Corporation and Immunex Corporation. He has been a major participant in regulatory approvals for six biopharmaceutical products now commercially available in the U.S. and in Europe, and has over 40 years of experience in the biologic and biopharmaceutical industry. John obtained his B.S. in Chemistry from Washington State University, and his Ph.D. degree in Organic/Analytical Chemistry from Colorado State University. He has served as a member of the PDA the Board of Directors, and is currently the chair of the PDA Biopharmaceutical Advisory Board. He is US Regulatory Affairs Certified (RAC) by the Regulatory Affairs Certification Board (RACB).

Thursday, 7June 2018

9:00
Welcome & Introduction


9:10
Understanding the Basics

  • Painting the terminology landscape: ATMP, HCT/P, GMP, Quality System, etc.
  • Introduction to the risk-based, phase-appropriate GMP and Quality approach

10:30
Coffee Break

11:00
Major Differences, and the Regulatory Consequences

  • Viruses/cells are not biologic proteins
  • GMP and Quality consequences of the differences between gene / cell-based medicines and protein-based medicines

12:30
Lunch Break

13:30
Regulatory Authority (EMA/FDA) Expectations

  • Regulatory authority risk-based considerations to ATMP GMPs and Quality
  • Regulatory authority guidances for a phase-appropriate approach to ATMP GMPs
    and Quality

15:00
Coffee Break

15:30
Industry Practice in Applying Phase-Appropriate GMPs and Quality to ATMPs

  • Adapting PDA Technical Report 56 as a model for phase-appropriate ATMP GMPs
    and Quality
  • Lesson learned from industry

17:30
End of Training Course

3 Ways to register

Please remember to log in if you are a member of PDA already! 

If you come from a Governmental or Health Authority Institution or from an Academic Organization please contact Ms. Antje Petzholdt before registering. She will verify your status and register you.

  • All registrations which will involve visa matters will have to be submitted to PDA EU four weeks prior to the start of the event at the latest. For later registrations, PDA Europe will be unable to assist participants in any visa affairs.
  • All costs incurring in connection with visa affairs shall be borne by registrants. (This applies in particular to costs for submitting documents by courier.)
  • Potential participants must be clients of UPS shipping agency and submit their UPS customer reference number to PDA EU (together with their registration).
  • No PDA membership obtainable upon booking training course, workshop or other related event.

Registration Fees

Are you entiteld to receive a discount? Need Help?

All Participants

845 Euro

All fees given in Euro and excluding VAT (21%)

Contact

Antje PetzholdtAntje Petzholdt
Manager Registration, Chapters & Membership
Tel: +49 (0) 30 43 655 08-10
Fax: +49 (0) 30 43 655 08-66

Exterior

Novotel Amsterdam Schiphol Airport Hotel
Taurusavenue 12
2132 LS Hoofdoorp
Netherlands
Tel: +31207219180
Hotel Website

Drop your bags at Novotel and relax. Novotel Amsterdam Airport Schiphol is a beautifully designed hotel at a very convenient location, within walking distance of Hoofddorp Station, 4 minutes by train from Amsterdam Airport Schiphol and 20 min by train from Amsterdam's city centre. It is the perfect hotel to explore Amsterdam and the region or for organizing a meeting or congress. Discover the excellent service and first class facilities of this brand new flagship property.

Thanks to its location close to Amsterdam Airport and with quick access to the city centre this hotel is the perfect spot to explore Amsterdam and the rest of the region. It is also the perfect venue for a good night sleep before an early flight. Nice walking and cycling tracks are located just outside the hotel and bikes are available for rent. You can also jump on the train and visit one of the many museums in Amsterdam or take a tour on the canals. In spring, the famous Keukenhof is a must-see.

PDA Europe has reserved a limited number of rooms until the 30th March 2018.
Book your room for the PDA Group Rate.

Single Room € 159 per night*
Double Room € 179 per night*

*Rates are per room and night, including the following services and benefits free of charge:
  • Buffet Breakfast in the restaurant
  • Wireless Internet Connection (WI-FI)
  • VAT, Taxes and Service Charge will apply

How to Get There

Amsterdam Airport Schiphol – AMS
Airport Phone: +31 20 794 0800

Hotel direction: 3.9 miles

Parking

  • Public indoor parking (Paying)

Photos

Sponsorship and Exhibit Opportunities are Available!

For more information about exhibit and sponsorship opportunities, please contact:

Nadjeschda Gomez-Stahl
Manager Exhibition & Sponsorship
Tel: +49 (0) 30 43 655 08-23
Fax: +49 (0) 30 43 655 08-66
Email

Register Now
https://store.pda.org/Meetings/Login.aspx?ID=4054

Directions